Maximilian Konig, M.D.

Maximilian Ferdinand Konig, M.D.

Headshot of Maximilian Konig
  • Director, Cellular Therapy Program (Autoimmunity), Department of Medicine
  • Assistant Professor of Medicine

Specializes in: Adults (18+ years)

Male

Languages: English, German

Expertise

Autoimmune Diseases, Auto-inflammatory Diseases, Rheumatology ...read more

Research Interests

rheumatic disease; autoimmunity; immuno-oncology; antigen-specific immunotherapy; CAR-T cells; rheumatoid arthritis; antiphospholipid syndrome; systemic lupus erythematosus ...read more

Locations

The Johns Hopkins Hospital

600 N. Wolfe Street
Baltimore, MD 21287
The Johns Hopkins Hospital - Google Maps

Johns Hopkins Bayview Medical Center

5501 Hopkins Bayview Circle
JHAAC 1B1
Baltimore, MD 21224
Johns Hopkins Bayview Medical Center - Google Maps

Background

Dr. Maximilian Konig is an Assistant Professor of Medicine in the Division of Rheumatology and Director of the Cellular Therapy Program (Autoimmunity) in the Department of Medicine at the Johns Hopkins University School of Medicine. He received his medical degree from Charité - Universitätsmedizin Berlin, Humboldt-Universität zu Berlin (Germany) and completed his residency training in the Stanbury Physician-Scientist Pathway at Massachusetts General Hospital, Harvard Medical School. Dr. Konig concluded subspecialty training in Clinical and Molecular Rheumatology as well as Advanced Rheumatology at Johns Hopkins Hospital.

His clinical interests lie in treating patients with systemic autoimmune diseases, including myositis, scleroderma, lupus, vasculitis, and inflammatory arthritis.

...read more

Titles

  • Director, Cellular Therapy Program (Autoimmunity), Department of Medicine
  • Assistant Professor of Medicine

Departments / Divisions

Centers & Institutes

Education

Degrees

  • MD; Charite - Universitatsmedizin Berlin -Humboldt-Universitat zu Berlin (2012)

Residencies

  • Medicine; Massachusetts General Hospital (2018)

Fellowships

  • Clinical and Molecular Rheumatology; Johns Hopkins University School of Medicine (2020)
  • Advanced Rheumatology; Johns Hopkins University School of Medicine (2021)

Board Certifications

  • American Board of Internal Medicine (Internal Medicine) (2019)
  • American Board of Internal Medicine (Rheumatology) (2021)

Research & Publications

Research Summary

As a physician-scientist in the Ludwig Center for Cancer Genetics and Therapeutics & Howard Hughes Medical Institute at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Dr. Konig’s research focuses on developing precision immunotherapies for the treatment of rheumatic diseases and cancer. A primary goal of his translational research program is the development of antigen-specific and personalized immunotherapies for autoimmune diseases, with the intent to achieve disease control without impairing normal immune responses that protect from infection.

Dr. Konig has a long-standing interest in mechanisms of disease initiation and propagation in autoimmune rheumatic and inflammatory disease. His postdoctoral research in the Division of Rheumatology elucidated how specific bacteria may cause loss of immunological tolerance and the development of anti-citrullinated protein antibodies (ACPAs) in rheumatoid arthritis, a hallmark of this autoimmune disease. This work identified Aggregatibacter actinomycetemcomitans as a pathogen that induces hypercitrullination and the release of citrullinated autoantigens from neutrophils during periodontal infection. These mechanistic findings may explain the clinical association of rheumatoid arthritis and gum disease and prove critical to research efforts to prevent the development of rheumatoid arthritis in high-risk individuals with evidence of preclinical autoimmunity.

Lab

Lab Website: Konig Lab

Technology Expertise Keywords

antigen-specific immunotherapy; T cell engineering; chimeric antigen receptor T-cell therapy; bispecific antibodies; protein citrullination

Clinical Trial Keywords

Chimeric antigen receptor (CAR) T-cell therapy; COVID-19-associated hyperinflammation

Clinical Trials

Dr. Konig leads clinical trials advancing chimeric antigen receptor (CAR)-T cell therapies for the treatment of severe and refractory autoimmune diseases at Johns Hopkins.

Selected Publications

View all on PubMed

Konig MF. The rise of precision cellular therapies. Nat Rev Rheumatol. 2024 Feb;20(2):69-70. doi: 10.1038/s41584-023-01073-6. PMID: 38191701

Hsiue EH, Wright KM, Douglass J, Hwang MS, Mog BJ, Pearlman AH, Paul S, DiNapoli SR, Konig MF, Wang Q, Schaefer A, Miller MS, Skora AD, Azurmendi PA, Murphy MB, Liu Q, Watson E, Li Y, Pardoll DM, Bettegowda C, Papadopoulos N, Kinzler KW, Vogelstein B, Gabelli SB, Zhou S. Targeting a neoantigen derived from a common TP53 mutation. Science. 2021 Mar 5;371(6533):eabc8697. doi: 10.1126/science.abc8697. Epub 2021 Mar 1. PMID: 33649166; PMCID: PMC8208645

Paul S, Pearlman AH, Douglass J, Mog BJ, Hsiue EH, Hwang MS, DiNapoli SR, Konig MF, Brown PA, Wright KM, Sur S, Gabelli SB, Li Y, Ghiaur G, Pardoll DM, Papadopoulos N, Bettegowda C, Kinzler KW, Zhou S, Vogelstein B. TCR β chain-directed bispecific antibodies for the treatment of T cell cancers. Sci Transl Med. 2021 Mar 10;13(584):eabd3595. doi: 10.1126/scitranslmed.abd3595. Epub 2021 Mar 1. PMID: 33649188

Konig MF, Powell M, Staedtke V, Bai RY, Thomas DL, Fischer N, Huq S, Khalafallah AM, Koenecke A, Xiong R, Mensh B, Papadopoulos N, Kinzler KW, Vogelstein B, Vogelstein JT, Athey S, Zhou S, Bettegowda C. Preventing cytokine storm syndrome in COVID-19 using α-1 adrenergic receptor antagonists. J Clin Invest. 2020 Jul 1;130(7):3345-3347. doi: 10.1172/JCI139642. PMID: 32352407; PMCID: PMC7324164

Konig MF, Abusleme L, Reinholdt J, Palmer RJ, Teles RP, Sampson K, Rosen A, Nigrovic PA, Sokolove J, Giles JT, Moutsopoulos NM, Andrade F. Aggregatibacter actinomycetemcomitans-induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis. Sci Transl Med. 2016 Dec 14;8(369):369ra176. doi: 10.1126/scitranslmed.aaj1921. PMID: 27974664; PMCID: PMC5384717

Academic Affiliations & Courses

Courses and Syllabi

  • Translational Science - Immunology (ME.800.649.0000.SP24)

Activities & Honors

Honors

  • Harrington Scholar-Innovator, Harrington Discovery Institute, 2023
  • Lupus Innovation Award, Lupus Research Alliance, 2023
  • Investigator Award, Rheumatology Research Foundation, 2023
  • Bisciotti Foundation Translational Award, Stephen And Renee Bisciotti Foundation, 2023
  • Distinguished Fellow Award, American College of Rheumatology, 2021
  • Jerome L. Greene Foundation Scholar Award, Jerome L. Greene Foundation, 2021
  • Jerome L. Greene Foundation Discovery Award, Jerome L. Greene Foundation, 2021
  • Peter and Carmen Lucia Buck Foundation Myositis Discovery Fund, Carmen Lucia Buck Foundation, 2021
  • Outstanding Research Award, Massachusetts General Hospital, Harvard Medical School, 2017
  • Albert L. Lehninger Young Investigator Award, Johns Hopkins University School of Medicine, 2016
  • Stabler Foundation Discovery Award, Donald B. and Dorothy L. Stabler Foundation, 2015
  • Scholar, German National Academic Foundation, German National Academic Foundation (Studienstiftung des deutschen Volkes), 2005
  • Biomedical MD Research Fellow, Boehringer Ingelheim Fonds, 2009

Memberships

  • American College of Rheumatology
  • American College of Physicians
  • American Society of Hematology

Professional Activities

  • Co-Chair, Abstract Selection Committee, Category Antiphospholipid Syndrome, American College of Rheumatology, 2023
  • Committee on Research, Early Career Investigators Subcommittee, American College of Rheumatology, 2021
  • Committee on Education, Abstract Oversight Subcommittee, American College of Rheumatology, 2021
  • Committee on Research, American College of Rheumatology, 2020
  • Board of Directors, Rheumatology Research Foundation, 2019
  • Committee on Journal Publications, American College of Rheumatology, 2018
  • Clinical and Scientific Committee, COVID-19 Global Rheumatology Alliance

Videos & Media

Recent News Articles and Media Coverage

  • Linking rheumatoid arthritis and gum disease: Researchers find common bacterium. Johns Hopkins HUB. (December 16, 2016)
  • How RA Begins: A Detective Story. LEAP Magazine. (Winter 2017)
  • Researchers Urge Clinical Trial of Blood Pressure Drug to Prevent Lethal Complication of Covid-19. Johns Hopkins News. (May 19, 2020)
  • Researchers at Johns Hopkins are racing to understand the connection between SARS-CoV-2 and a deadly immune system malfunction called a cytokine storm. Johns Hopkins HUB. (June 29, 2020)
  • CATCR-T cell therapy may aid in antiphospholipid syndrome through selective B-cell depletion. Healio Rheumatology. (November 30, 2022)
  • Transforming Treatment for Autoimmune Diseases. Johns Hopkins Center for Innovative Medicine: Breakthrough. (Winter 2023)
  • Can autoimmune diseases be cured? Scientists see hope at last. Nature. (January 23, 2024)
Is this you? Edit Profile
back to top button